- Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aprepitant; Drug: placebo
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified April 2012 - Condition: Opioid Dependence
Interventions: Drug: Aprepitant; Drug: Placebo pill
Sponsors: New York University; New York University; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Conditions: Gastrointestinal Cancer; Nausea Post Chemotherapy
Intervention: Drug: fosaprepitant dimeglumine
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012 - Conditions: Sarcoma; Chemotherapy-induced Nausea and Vomiting; Effects of Chemotherapy; Adverse Effects of Medical Drugs
Interventions: Drug: Fosaprepitant; Drug: Dexamethasone; Drug: 5HT3 receptor antagonist; Drug: Ifosfamide-based chemotherapy (AI); Drug: Doxorubicin; Drug: Mesna; Drug: Ifosfamide; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Not yet recruiting - verified March 2012 - Conditions: PONV; Nausea
Interventions: Drug: Aprepitant; Drug: Ondansetron
Sponsors: Ohio State University; Sergio Bergese
Recruiting - verified November 2011 - Conditions: Nausea; Vomiting; Glioma
Interventions: Drug: Aprepitant and Ondansetron; Drug: Ondansetron
Sponsors: Duke University; Duke University; Merck
Not yet recruiting - verified March 2012 - Conditions: Postoperative Nausea and Vomiting; Genetic Polymorphisms
Interventions: Drug: Ondansetron; Drug: Lorazepam; Drug: Aprepitant
Sponsors: University of California, San Francisco; University of California, San Francisco; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Aprepitant and Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011 - Condition: Chemotherapy Induced Nausea and Vomiting
Interventions: Drug: Aprepitant 125 mg; Drug: Aprepitant 80 mg; Drug: Aprepitant PFS; Drug: Ondansteron; Drug: Placebo for Aprepitant 125 mg; Drug: Placebo for Aprepitant 80 mg; Drug: Placebo for Aprepitant PFS
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Cocaine; Alcohol Dependence
Interventions: Drug: Aprepitant; Drug: Placebo
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011 - Condition: Gastroparesis
Interventions: Drug: Aprepitant; Drug: Placebo
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified October 2011 - Condition: Head and Neck Cancer
Interventions: Other: radiation combined with weekly carboplatin; Procedure: conservation surgery
Sponsors: Southern Illinois University; Southern Illinois University
Recruiting - verified March 2012 - Conditions: Breakthrough Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: fosaprepitant dimeglumine; Drug: systemic chemotherapy; Other: survey administration; Procedure: quality-of-life assessment
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Nausea; Vomiting
Interventions: Drug: aprepitant; Drug: Ondansetron
Sponsors: University of Vermont; University of Vermont; Mayo Clinic; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified March 2012 - Conditions: Hematologic Diseases; Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
Interventions: Drug: Ondansetron; Drug: Aprepitant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Conditions: Nausea; Vomiting
Intervention: Drug: fosaprepitant
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute
Recruiting - verified December 2011 - Conditions: Alcoholism; Alcohol Dependence; Post-Tramatic Stress Disorder; fMRI
Intervention: Drug: Aprepitant
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified December 2011 - Condition: Postoperative Nausea and Vomiting
Interventions: Drug: aprepitant; Drug: Comparator: Ondansetron
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: fosaprepitant; Drug: Experimental: fosaprepitant; Drug: Experimental: fosaprepitant; Drug: Comparator: ondansetron
Sponsors: Merck; Merck
Recruiting - verified May 2012
 |
Aprepitant Clinical Trials |
